Student Outcomes

Student Outcomes:
  • 75% of QSB graduates who applied to Ph.D. programs have been admitted (Northwestern University, U of Wisconsin, U of Washington, UC Irvine, Washington University St. Louis, Georgia Tech, U of Tennessee Health Science Center, U of Illinois Urbana-Champaign, U of Toronto - Canada, École Polytechnique Fédérale de Lausanne - Switzerland, McGill University - Canada, Humboldt University - Germany, Shanghai Institute of Biochemistry and Cell Biology, University Medical Center Groningen - Netherlands)
  • Some students have specifically chosen to go to industry (Bain and Company, and Vizient, Inc.) and did not apply for Ph.D. programs 
  • Students who have not gone into Ph.D. programs have gone onto productive careers in academic research and biotech (Institute of Materia Medica -China, New Bellus - Taiwan)
Class of 2026 (8 students)
  • 5 applied for Ph.D. programs, 3 with offers, one pending
Class of 2025 (8 students;  incomplete data as some students have pending offers)
  • 3 in Ph.D. programs: U of Washington, Shanghai Institute of Biochemistry and Cell Biology, University Medical Center Groningen
  • 1 Visiting Researcher
Class of 2024 (4 students)
  • 3 in Ph.D. programs: Northwestern University’s IBiS program, Washington University St. Louis
Class of 2023 (4 students)
  • 3 in Ph.D. programs: Northwestern University’s IBiS program, U of Illinois Urbana-Champaign, École Polytechnique Fédérale de Lausanne - Switzerland
Class of 2022 (5 students)
  • 5 in Ph.D. programs: Northwestern University's IBiS program, Georgia Tech, U of Tennessee Health Science Center
Class of 2021 (4 students)
  • 1 in Ph.D. programs: Northwestern University's IBiS program
Class of 2020 (4 students)
  • 3 in Ph.D. programs: Northwestern University's IBiS program, Humbolt University - Germany
Class of 2019 (6 students)
  • 5 in Ph.D programs: U of Washington, McGill University - Canada, Washington University St. Louis, UC Irvine